SAN DIEGO, June 17, 2020 (GLOBE NEWSWIRE) -- Cellics Therapeutics, Inc.. (Cellics) announced today that results of the study that evaluates the potential benefits of macrophage and pulmonary epithelial nanosponges in neutralizing SARS-CoV-2 infectivity have been published in Nano Letters, entitled Cellular Nanosponges Inhibit SARS-CoV-2 Infectivity, based on research conducted by its founder, Liangfang Zhang, Ph.D.http://pubs.acs.org/doi/abs/10.1021/acs.nanolett.0c02278
As new information about COVID-19 continues to emerge almost on a daily basis, the virus has already demonstrated its ability to mutate and became more infectious, raising doubts about the viability of an effective vaccine and potential future therapies. A therapy that is agnostic to future mutations and has the potential to address future novel viral pandemics is extremely attractive. Treatments that target the affected host cell rather than the infectious agent may offer an opportunity to address future mutations and novel viral outbreaks.
The published study was initiated to evaluate the potential of nanosponges derived from human cells as a therapeutic for the treatment of COVID-19. The study was a collaborative effort between the Department of NanoEngineering at the University of California San Diego Jacobs School of Engineering and the Department of Microbiology and National Emerging Infectious Diseases Laboratories at the Boston University School of Medicine.
Nanosponges derived from macrophages and human pulmonary epithelial cells were tested as it is understood that SARS-CoV-2 enters the cells via known receptors (ACE-2 and CD147) and maybe other unknown receptors. Macrophage and pulmonary epithelial nanosponges were incubated with SARS-CoV-2 infected cells to assess if nanosponges are able to neutralize live SARS-CoV-2 virus. Both macrophage and pulmonary epithelial cell nanosponges demonstrated significant neutralization of SARS-CoV-2 infectivity after two hours of incubation in a concentration dependent manner.
This data represents a validation of the nanosponge platform and our approach of identifying the affected host cell to develop nanosponges as a therapy, said Steve Chen, MD, President and Chief Medical Officer, Cellics Therapeutics. The nanosponge technology allows the therapy to be mutation and virulence factor agnostic, making it a potential universal anti-viral agent for future viral outbreaks. Previous work has shown that macrophage nanosponges neutralized inflammatory cytokines, which are involved in the cytokine storms described in COVID-19 patients. We are particularly excited with the macrophage nanosponges data as a potential therapy to neutralize both the viral activity and the downstream complications associated with COVID-19. We look forward to further validation studies and mapping out a potential path forward to deliver this promising therapy to patients.
Cellics holds exclusive global rights for the development and commercialization of red blood cell and white blood cell nanosponges, including macrophage nanosponges for treatment of various diseases from the University of California, San Diego. Currently, Cellics is developing macrophage nanosponges for the treatment of sepsis.
About Nanosponge Platform Technology
Our proprietary platform technology strips cell membranes of their intracellular contents and allows us to create nanosponges from these membranes to be leveraged as a therapeutic product (Nanosponge Technology). These nanosponges are designed to counteract diverse disease pathologies by acting as biomimetic decoys to sequester and neutralize biological molecules that would otherwise attack host cells. Examples of such harmful agents include toxins, inflammatory cytokines and viruses. The cell membrane forming the outer layer of the nanosponges is selected according to the disease pathology, specifically which host cells are under attack. Nanosponges leverage the natural bioactivity of human cell membrane receptors for therapeutic efficacy. With the advantage of their small size and large quantity, nanosponges outcompete host cells in binding and sequestering biological molecules.
Product development currently emphasizes the use of nanosponges made of human red blood cell membrane and white blood cell membrane for the treatment of bacterial infections and inflammatory diseases. A similar working principle can be applied with membranes of other cell types, making nanosponges suitable for large and diverse disease areas. We have achieved proof of concept in animal models in a range of disease areas.
About Cellics
Cellics Therapeutics, Inc. (Cellics or Company) is a privately held development stage pharmaceutical company founded in 2014 by UC San Diego professor Liangfang Zhang based on his award-winning Nanosponge Technology. Cellics was created with the goal of applying the Nanosponge Technology to treat and prevent diseases.
Cellics is committed to saving lives and improving patients health using innovative biomimetic nanomedicines. The Companys primary focus at this time is on autoimmune and inflammatory diseases and difficult-to-treat infectious diseases. Cellics also aims to develop best-in-class vaccines for various diseases. The Company is currently on schedule to advance its lead product candidate CTI-005 to human clinical trials for the treatment of MRSA pneumonia.
It is the passion and goal of Cellics to use advanced technology to help patients live healthier and longer lives. Visit us at cellics.com.
About UC San Diego Jacobs School of Engineering
The Jacobs School of Engineering at the University of California San Diego offers excellence at scale in research, education, public service, and technology transfer. The Jacobs School ranks first among all public engineering schools for research expenditures per faculty member. These entrepreneurial faculty lead teams that work across disciplines and industries to tackle the toughest challenges that no lab, department or company can handle alone. At the Jacobs School of Engineering, we make bold possible. Visit us athttp://jacobsschool.ucsd.edu/
Forward-looking Statements
This press release contains forward-looking statements, as that term is defined in the Private Securities Litigation Reform Act of 1995. These statements are only predictions and involve known and unknown risks, uncertainties and other factors, any one of which may cause actual results to be materially different from these forward-looking statements. These factors include, without limitation, the ability to duplicate the study results in future studies; the timing and success of our development of CTI-005, CTI-008, CTI-105, CTI-108, and other pipeline candidates; the ability to successfully scale-up our manufacturing process; the timing, costs, conduct, and outcome of our clinical study; and the indication(s) for which our pipelines may be developed. The forward-looking statements in this press release reflect the Company's judgment as of the date of this press release. The Company disclaims any intent or obligation to update these forward-looking statements. This press release shall not constitute an offer to sell or the solicitation of an offer to buy nor shall there be any sale of our securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
Contacts
Steve Chen, MDPresident and Chief Medical OfficerCellics Therapeutics, Inc.(858) 412-6148schen@cellics.com
UC San Diego Media ContactIoana PatringenaruPublic Information RepresentativePhone: 858-822-0899ipatrin@ucsd.edu
Source: Cellics Therapeutics, Inc.
- Nano Medicine: Meaning, Advantages and Disadvantages - BioTechnology Notes - December 18th, 2022
- www.the-scientist.com - December 18th, 2022
- Applications of Nanotechnology - National Nanotechnology Initiative - December 18th, 2022
- Nanotechnology Timeline | National Nanotechnology Initiative - October 29th, 2022
- Nano based drug delivery systems: recent developments and future ... - October 21st, 2022
- The Application of Nanotechnology and Nanomaterials in Cancer Diagnosis and Treatment: A Review - Cureus - September 16th, 2022
- 'Glass bubble' nanocarrier boosts effects of combination therapy for pancreatic cancer - UCLA Newsroom - September 16th, 2022
- International Conference (Sep. 15-17) on Advances in Molecular Diagnostics and Precision Medicine (AMDP-2022.. - ETHealthWorld - September 16th, 2022
- Reebok Nano X2 Adventure Review: A Wild Way to Log Your Workouts - Gear Patrol - August 30th, 2022
- PhD within Particle Engineering job with NORWEGIAN UNIVERSITY OF SCIENCE & TECHNOLOGY - NTNU | 306487 - Times Higher Education - August 30th, 2022
- Nanoparticles' Role in Eliminating Cancer Cells - MedTech Outlook - August 22nd, 2022
- The first female astronaut from a North African nation will be a Tunisian military aviator - Atalayar - August 22nd, 2022
- Fast and noninvasive electronic nose for sniffing out COVID-19 based on exhaled breath-print recognition | npj Digital Medicine - Nature.com - August 22nd, 2022
- Reebok's Nano X2 Adventure Helps You Take Your Workouts Anywhere - Gear Patrol - August 14th, 2022
- How Houston's nonprofit funds early research that leads to breakthroughs like the COVID vaccine - Houston Chronicle - August 14th, 2022
- Ponce Therapeutics Executes Worldwide Exclusive License to Speratum Biopharma's Nano-in and No-Pass Mimic Nanoparticle Technologies in Anti-Aging and... - July 27th, 2022
- Nanorobots Market to close to USD 19576.43 million with CAGR of 12.23% during the forecast period to 2029 - Digital Journal - July 27th, 2022
- Aviceda Therapeutics Announces Key Opinion Leader in Ophthalmology Drug Development Tarek S. Hassan, MD to Join Management Team as Chief Development... - July 27th, 2022
- Second Sight Medical Products Announces Year Four NIH Funding of its Orion Study - Business Wire - July 19th, 2022
- Columbia Business School and Columbia Engineering to Offer New "Dual MBA/Executive MS in Engineering and Applied Science" Program - Yahoo... - July 19th, 2022
- Internet of Nano Things Market is Poised to Grow at a CAGR of 24.12% during the Forecast Period of 2022-2031 - Digital Journal - July 11th, 2022
- Notable Thermal and Mechanical Properties of New Hybrid Nanostructures - AZoM - July 11th, 2022
- Eggshell and bioceramics: Break an egg to fix a tooth or two - BusinessLine - July 11th, 2022
- Nanomedicine in Central Nervous System Injury and Repair Market Share, Regional Growth Analysis, Upcoming Trends, Growth Factors and Leading... - July 11th, 2022
- Nanorobotics Market 2022 Research Report Analysis from Perspective of Segmentation and Industry Growth 2030 Designer Women - Designer Women - July 11th, 2022
- Artificial Intelligence in Medical Diagnostics Market Worth $9.38 Billion by 2029 - Exclusive Report by Meticulous Research - GlobeNewswire - July 11th, 2022
- $2.38M to test nano-engineered brain cancer treatment in mice - University of Michigan News - June 22nd, 2022
- New Amrita Hospital is all set to open in Faridabad in August this year; 2,400-bed facility will become Indias biggest private hospital - The... - June 22nd, 2022
- Global Advanced Functional Materials Market To Be Driven By The Surging Demand From Medical Sector In The Forecast Period Of 2021-2026 Designer Women... - June 22nd, 2022
- An effective nano drug delivery and combination therapy for the treatment of Tuberculosis | Scientific Reports - Nature.com - June 13th, 2022
- Nanotechnology is poised to shape the future of Healthcare - ETHealthWorld - June 4th, 2022
- New Silence ALS Initiative is Giving Hope to Nano-Rare Patients - BioSpace - June 4th, 2022
- Nanotechnology in the Global Medical Applications Market 2022, Featuring Profiles of Abbott, Abraxis Bioscience, Elan, Orthovita, EyePoint... - May 15th, 2022
- Nano state: tiny and now everywhere, how big a problem are nanoparticles? - The Guardian - May 2nd, 2022
- Nanomedicine Market to 2030 Insights and Forecast with Impact of COVID-19 | Abbott Laboratories, DiaSorin S.p.A, Invitae Corporation, Mallinckrodt... - May 2nd, 2022
- Cancer and Nanotechnology - National Cancer Institute - April 19th, 2022
- Nanobots/Nanorobots Market Overview, Merger and Acquisitions , Drivers, Restraints and Industry Forecast By 2028 - Digital Journal - April 19th, 2022
- ERDC researchers analyze resilience in nanotechnology supply chains - erdc.usace.army.mil - April 19th, 2022
- Nano Products Online Store | Nanoproducts, Nanoparticles ... - April 6th, 2022
- The Conrad Prebys Foundation to Support the Discovery and Development of Personalized ASO Medicines for Nano-rare Patients - Business Wire - March 25th, 2022
- Space the next frontier for cancer treatment? - Australian Jewish News - March 25th, 2022
- ViaCyte Strengthens Management Team with Appointment of Alyssa Levin as Chief Financial Officer and Addition of Lisa Porter, MD, to the Board of... - January 20th, 2022
- Surface Modification and Size Contribute to Nanoplastic Toxicity - AZoNano - January 20th, 2022
- Frontiers | Nanomedicine: Principles, Properties, and ... - January 5th, 2022
- Nanotechnology In Medicine: Huge Potential, But What Are ... - January 5th, 2022
- Stem Cell Mimicking Nanoencapsulation for Targeting Arthrit | IJN - Dove Medical Press - January 5th, 2022
- 2009 show based on conspiracy theories is shared as proof of WHO working on COVID-19 vaccines to create permanent sterility - Factly - January 5th, 2022
- How to Improve Infectious Diseases with Nanotechnology - CIO Applications - January 5th, 2022
- Biodistribution of sphingolipid nanoemulsions with 68Ga | IJN - Dove Medical Press - August 31st, 2021
- Matrix Meats Adds to Team as Interest in Cultivated Meat Grows - PRNewswire - July 21st, 2021
- Nanomedicine in Central Nervous System Injury and Repair Market Report- Trends Key Programs Analysis and Competitive Landscape Analysis The Manomet... - June 23rd, 2021
- Nanomedicine is transforming healthcare innovation - Korea IT Times - June 6th, 2021
- The Future of Cancer Treatment Using Nanotechnology - AZoNano - June 6th, 2021
- Thomas Jefferson Awards Highlight Research and Service to the University - UVA Today - June 6th, 2021
- Global Nanobots Market 2020 | Research Report Covers | (COVID-19 Analysis) | Industry Research, Drivers, Top Trends | Global Analysis And Forecast to... - October 31st, 2020
- Nanox Signs With Ambra Health to Enable Image Access and Transfer with US Hospitals and Medical imaging Providers - BioSpace - October 31st, 2020
- Global Nano Therapy Market- Industry Analysis and Forecast (2020-2027) - Stock Market Vista - October 29th, 2020
- What is Nanoscience? | Outlook and How to Invest | INN - Investing News Network - September 23rd, 2020
- Interview: The NDB team on its revolutionary nano-diamond batteries - New Atlas - August 29th, 2020
- Opportunities in the World Nanotechnology Market to 2025 - Application of Nanotechnology in Wastewater Treatment and Enhanced Renewable Energy Driving... - August 12th, 2020
- Nanocellulose Market to Reach USD 1.08 Billion by 2027 | CAGR:20.4% | Reports And Data - PRNewswire - June 17th, 2020
- Coronavirus threat to global Healthcare Nanotechnology (Nanomedicine) Market 2020 Industry Share, Size, Consumption, Growth, Top Manufacturers, Type... - June 15th, 2020
- Kanazawa University Research: Cell Removal as the Result of a Mechanical Instability - PR Newswire UK - June 15th, 2020
- Impact of Covid-19 on Nano Chemotherapy Market is Expected to Grow at an active CAGR by Forecast to 2026 | Top Players Dell Wyse, IBM, Microsoft -... - June 15th, 2020
- Evergreen Medical Acupuncture is now offering its own supplement and herbal products, Dr. Ficks Functional Farmacy! - TippNews DAILY - June 10th, 2020
- Inolife is going to revolutionize how we take our medicine - BNNBloomberg.ca - May 24th, 2020
- Recent Progress and Future Directions: The Nano-Drug Delivery System f | IJN - Dove Medical Press - May 10th, 2020
- The future of medicine - Switzer Financial News - May 10th, 2020
- All your questions about how to wear a face mask -- answered - Action News Now - April 26th, 2020
- Edited Transcript of NANO earnings conference call or presentation 6-Feb-20 9:30pm GMT - Yahoo Finance - February 11th, 2020
- Kanazawa University Research: Combined Drug Treatment for Lung Cancer and Secondary Tumors - Yahoo Finance - February 11th, 2020
- Immix Doses First Patient in USA in its Phase 1b/2a Trial in Patients with Advanced Solid Tumors - BioSpace - February 11th, 2020
- Nano Medicine: Meaning, Advantages and Disadvantages - February 6th, 2020
- The Future Of Nano Medicine - February 6th, 2020
- VVUS Stock Jumps 70% on FDA Nod for New Formulation of Pancreaze - MicroSmallCap - February 6th, 2020
- Is the Lieber Arrest Linked to Military Brain Research and China? - Bryen's Blog - February 6th, 2020
- A Chelate-Free Nano-Platform for Incorporation of Diagnostic and Thera | IJN - Dove Medical Press - January 10th, 2020
- Examine Triple Negative Breast Cancer Treatment Market expected to reach US$ 720 mn by 2026 - WhaTech Technology and Markets News - January 10th, 2020
- Triple Negative Breast Cancer Treatment Market Combining Therapies - Communal News - January 10th, 2020
- Our top 20 features of 2019 - COVER - January 5th, 2020